Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
A composition includes a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
1. A composition comprising a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
2. The composition of claim 1 , wherein the dosage form includes 45% w/w to 90% w/w of a water soluble polymer in the polymer carrier matrix.
3. The composition of claim 1 , wherein the polymer carrier matrix includes gelatin.
4. The composition of claim 1 , wherein polymer carrier matrix includes at least one water soluble polymer selected from the group consisting of polyethylene oxide, maltodextrin, hydroxypropyl methylcellulose, hydroxypropyl cellulose, starch, modified starch, pullan, gelatin, and carboxymethyl cellulose.
5. The composition of claim 1 , wherein the dosage form includes 1% to 20% w/w surfactant.
6. The composition of claim 5 , wherein the surfactant includes at least one surfactant selected from the group consisting of sodium lauryl sulfate, benzalkonium chloride, benzethonium chloride, polysorbate 20, cetearyl alcohol, glyceryl surfactants, and cetyl pyridinium chloride.
7. The composition of claim 1 , wherein the pH is 2 to 4.
8. The composition of claim 1 , wherein the disintegrant is 6% w/w to 20% w/w of the dosage form.
9. The composition of claim 1 , wherein the acid is 20% w/w to 30% w/w of the dosage form.
10. The composition of claim 1 , wherein the acid is 5% w/w to 20% w/w of the dosage form.
11. The composition of claim 1 , wherein the therapeutically effective amount of melatonin is 0.2 mg to 20 mg.
12. The composition of claim 1 , wherein the acid is a carboxylic acid.
13. The composition of claim 1 , wherein the acid is citric acid.
14. A method comprising administering a composition comprising a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
15. The method of claim 14 , wherein the dosage form includes 45% w/w to 90% w/w of a water soluble polymer in the polymer carrier matrix.
16. The method of claim 14 , wherein the polymer carrier matrix includes gelatin.
17. The method of claim 14 , wherein the polymer carrier matrix includes at least one water soluble polymer selected from the group consisting of polyethylene oxide, maltodextrin, hydroxypropyl methylcellulose, hydroxypropyl cellulose, starch, modified starch, pullan, gelatin, and carboxymethyl cellulose.
18. The method of claim 14 , wherein the dosage form includes 1% to 20% w/w surfactant.
19. The method of claim 18 , wherein the surfactant includes at least one surfactant selected from the group consisting of sodium lauryl sulfate, benzalkonium chloride, benzethonium chloride, polysorbate 20, cetearyl alcohol, glyceryl surfactants, and cetyl pyridinium chloride.
20. The method of claim 14 , wherein the pH is 2 to 4.
21. The method of claim 14 , wherein the disintegrant is 6% w/w to 20% w/w of the dosage form.
22. The method of claim 14 , wherein the acid is 20% w/w to 30% w/w of the dosage form.
23. The method of claim 14 , wherein the acid is 5% w/w to 20% w/w of the dosage form.
24. The method of claim 14 , wherein the therapeutically effective amount of melatonin is 0.2 mg to 20 mg.
25. The method of claim 14 , wherein the acid is a carboxylic acid.
26. The method of claim 14 , wherein the acid is citric acid.